Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
D000109:Acetylcholine / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D001593:Benzyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D010881:Piperidones / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use
D001593:Benzyl Compounds; D010880:Piperidines; D010881:Piperidones; D010919:Placebos; D014149:Tranquilizing Agents; D006220:Haloperidol; D000109:Acetylcholine